Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography

Oxycodone (14‐hydroxy‐7,8‐dihydrocodeinone) is a potent opioid receptor agonist. In the present study, a liquid–liquid extraction‐based reversed‐phase HPLC method with UV detection was validated and applied for the analysis of oxycodone and its major metabolite, noroxycodone, in human plasma. The analytes were separated using a mobile phase, consisting of acetonitrile and phosphate buffer (8:92, v[sol ]v) at a flow rate of 1 mL[sol ]min, and UV detection at 205 nm. The retention times for oxycodone, noroxycodone and codein (internal standard) were 14.7, 13.8 and 10.2 min, respectively. The validated quantitation range of the method was 2–100 ng[sol ]mL for oxycodone and 10–100 ng[sol ]mL for noroxycodone. The developed procedure was applied to assess the pharmacokinetics of oxycodone and its metabolite following administration of a single 20 mg oral dose of oxycodone hydrochloride to one healthy male volunteer. Copyright © 2005 John Wiley & Sons, Ltd.